Mandate

PPM Ventures and Triton – acquisition of Pharmacia Diagnostics

May 12, 2005

Triton, the European private equity firm, and PPM Ventures Ltd, the private equity business within Prudential Corporation plc, the UK financial services group, has agreed to acquire Pharmacia Diagnostics AB, the Swedish based in-vitro allergy and autoimmune diagnostic testing business of Pfizer Inc, the US-based health care company, for USD 575m.

Vinge acted for Triton and PPM Ventures Ltd.

Johan Cederlund, Christina Kokko (responsible partners)
Sara Mindus (associate)

Related

Vinge has advised EQT AB in connection with the refinancing of EQT’s EUR 1,500,000,000 sustainability-linked revolving credit facility

The sustainability-linked credit facility has a tenor of 5 years with two 1-year extension options.
July 23, 2024

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.
July 19, 2024

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024